- . ( ) ( ()) - , ().
1. ,
1.1
˳ , , 6- ; ; .
1.2 -
˳ ( ):
1. b2- 䳿: , ;
2. b2- 䳿: , , ;
3. 䳿: ;
4. 䳿: ҳ ;
5. : , ;
6. : , , ;
7. : , ;
8. : , 4: ;
9. : + , +, +
10. : : , ; : + ; : , .
11. : , ճ, , , .
, ; ; 6- ; ; (, , , ) , .
2. ,
2.1
; ; ; ; ; , ; -, ; , , . , .
2.2 -
˳ ( ):
1. b2- 䳿: , ;
2. b2- 䳿: , , ;
3. 䳿: ;
4. 䳿: ҳ ;
5. : , ;
6. : , , ;
7. : , ;
8. : , 4: ;
|
|
|
9. : + , +, +
10. : : , ; : + ; : , .
11. : , ճ, , , .
12.
; ; , - ; ( ); ; ﳿ , .
V.
5.1.
1. .
2. , , .
3. ³ , .
4. ³ , .
5. ³ , , .
6. ³ , .
| ( 025/) | 025/ , 14.02.2012 . 110 , ' |
| ( 030/) | 030/ , 14.02.2012 . 110 , ' |
5.2.
5.2.1.) .
) , .
, (), () : .
) .
- () . , , , .
|
|
|
:
2013 50%
2014 90%
2015 100%.
) .
) ( ), : ' .
) - ( , - ), , ' .
) , .
) : .
' - ( , - ), . .
) - ( , - ), . ' , - ( , - ), .
) - ( , - ), , ( ). , - ( , - ).
) .
5.2.2.) , , .
) , .
, (), () : .
) .
- () . , , , .
:
2013 50%
2014 90%
2015 100%.
) .
) ( ), : ' .
) , , ' .
) , .
) : .
' , . .
|
|
|
) , . ' , - ( , - ), .
) , , ( ). , - ( , - ).
) .
5.2.3.) ³ , .
) , .
, (), () : .
) .
, .
ֳ () .
) .
) ( ), : ѳ ( , - ). .
) - ( , - ), , .
) , .
) : . 㳿 , , ( 025/) ( 030/) .
- ( , - ) ( 025/) ( 030/).
( , - ), , ( ), , , .
) , - ( , - ), . :
|
|
|
( 025/);
( 030/).
) , - ( , - ), , . :
( 025/);
( 030/).
) .
5.2.4.) ³ , .
) , .
, (), () : .
) .
, . ( , - ) . ֳ () .
) .
) ( ), : - ( , - ). .
) - ( , - ), , .
) , .
) : . 㳿 , , ( 025/) .
- ( , - ) , .
- ( , - ), , , .
) , - ( , - ), . :
( 025/);
( 030/).
) , - ( , - ), , . :
( 025/);
( 030/).
) .
5.2.5.) ³ , , .
) , .
, (), () : .
|
|
|
) . , , .
) .
) ( ), : - ( , - ). .
) - ( , - ), , .
) , .
) : . 㳿 , , ( 025/) .
- ( , - ) , .
( , - ), , , .
) , - ( , - ), . :
( 025/).
) , - ( , - ), ˻ , ( 025/) . :
( 025/).
) .
5.2.6.) ³ , .
) , .
, (), () : .
) . , - ( , - ) . , . , , , , - ( , - ) , ( ).
ֳ () .
) .
) ( ), : - ( , - ). .
) ( , - ), , .
) , .
) : . 㳿 , , ( 025/0) ( 030/) .
- ( , - ) ( 025/0) ( 030/).
- ( , - ), , , .
) , - ( , - ), . :
( 025/);
( 030/).
) - ( , - ), , .
:
( 025/);
( 030/).
) .
| ̳ | . |
Vll.
1. . , , 2012.
2. NICE Clinical Guideline No 12. Chronic obstructive pulmonary disease. Management of chronic obstructive pulmonary disease in primary and secondary care (partial update) (CG 101). NICE (GB) National Institute for Health and Clinical Excellence, Jun 01, 2010. www.nice.org.uk/CG012fullguideline www.nelh.nhs.uk
3. GOLD Global Initiative for Chronic Obstructive Lung Diseases, Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease, revised 2011 http://www.goldcopd.org/
4. : Chronic Obstructive Pulmonary Disease (COPD). Australian and New Zealand Management Guidelines and the COPD Handbook. Version 1 Jan 01, 2009. The Thoracic Society of Australia and New Zealand. The Australian Lung Foundation. [email protected]
5. VHA/DOD clinical practice guideline for the management of chronic obstructive pulmonary disease. Version 1.1a. National Guideline Clearinghouse. AHRQ. www.guideline.gov
6. . 2005. . www.society.
7. www.pulmonology.ru
8. 19.03.07 128.
9. 03.07.06 433.
10. Chronic obstructive pulmonary disease Management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update) This guideline partially updates and replaces NICE clinical guideline 12. Issue date: June 2010. NICE clinical guideline 101. Developed by the National Collaborating Centre for Acute and Chronic Conditions. http://www.nice.org.uk
11. Health Care Guideline: Diagnosis and Management of Chronic Obstructive Pulmonary Disease (COPD). Seventh Edition January 2009. Institute for clinicalsystems improvement (ICSI). www.icsi.org
12. National guideline clearinghouse (NGC) Guideline synthesis. Chronic obstructive pulmonary disease (COPD): pulmonary rehabilitation. Guidelines being compared: 1. American College of Chest Physicians/American Association of Cardiovascular and Pulmonary Rehabilitation (ACCP/AACVPR). Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest 2007 May;131(5 Suppl):4S-42S. 2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda (MD): Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2008. 94 p. 3. Singapore Ministry of Health (SMOH). Chronic obstructive pulmonary disease. Singapore: Singapore Ministry of Health; 2006 Oct. 84 p. 4. Department of Veterans Affairs, Department of Defense (VA/DoD). VA/DoD clinical practice guideline for management of outpatient chronic obstructive pulmonary disease Washington (DC): Department of Veteran Affairs, Department of Defense; 2007. 138 p. http://www.guideline.gov.
13. National guideline clearinghouse (NGC) Guideline synthesis. Chronic obstructive pulmonary disease (COPD): diagnosis and management of acute exacerbations. Guidelines being compared: 1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda (MD): Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2009. 93 p. 2. Singapore Ministry of Health (SMOH). Chronic obstructive pulmonary disease. Singapore: Singapore Ministry of Health; 2006 Oct. 84 p. 3. Department of Veterans Affairs, Department of Defense (VA/DoD). VA/DoD clinical practice guideline for management of outpatient chronic obstructive pulmonary disease. Washington (DC): Department of Veteran Affairs, Department of Defense; 2007. 138 p. http://www.guideline.gov.
14. National guideline clearinghouse (NGC) Guideline synthesis. Diagnosis and management of stable chronic obstructive pulmonary disease (COPD). Guidelines being compared: 1. American College of Physicians (ACP). Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2007 Nov 6;147(9):633-8. 2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda (MD): Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2008. 94 p. 3. Singapore Ministry of Health (SMOH). Chronic obstructive pulmonary disease. Singapore: Singapore Ministry of Health; 2006 Oct. 84 p. http://www.guideline.gov.
15. Two new studies in COPD: 1. Combined LABA/ICS versus LABA alone in COPD - few clinical benefits but increasedserious adverse effects. 2. Triple therapy with LABA/ICS plus tiotropium in COPD. MeReC Monthly No.22, January 2010 http://www.npc.co.uk/ebt/merec/resp/copd/merec_monthly_no22.html
16. The treatment and prevention of exacerbations in COPD:the role of primary care. Adapted from NICE 2004. British Lung Foundation. www.lunguk.org
Vlll.
| 1. | , |
| 2. | . |
| 3. | . |
| 4. | |
| 5. | ' |
| 6. | |
| 7. | . |
| 8. | |
| 9. | |
| 10. | ﳿ, , . |
| 11. | , - |
| 12. | - |
| 13. | 㳿 |
1
, (),
. ij , , , , .
:
| . | |
| . | |
| , , ' . | |
| 100 . | |
| ' . |
2
, (),
()? (COPD Assessment Test (CAT))
( ) . , .
:
(-)      
|
| () | () | ||||||
| , | , | ||||||
| - | |||||||
| , , | , | ||||||
| 㳿 | 㳿 |
.
≥2 ≥10 .
3
, (),
.
4 .
1/ƪ < 70 %, 1: ( 1 ).
| 1 (% ) | ||
| ³ 80 | ||
| 50 £ 1 < 80 | ||
| 30 £ 1 < 50 | ||
| 1 < 30 |
, , , , / . , ³2 ³10 ( , , . , ).
, , , . . , : 3 4 - (1<50 % ) . : 2 .
, . , .
| GOLD | C | D | ≥ 2 | ||
| A | B | ||||
| < 2 | ≥ 2 | ||||
| < 10 | ≥ 10 | ||||
,
, GOLD 1 GOLD 2 / ≤ 1 < 2 <10
B ,
, GOLD 1 GOLD 2 / ≤ 1 ≥ 2 ≥10
,
, GOLD 3 GOLD 4 / ≥ 2 < 2 <10
D ,
, GOLD 3 GOLD 4 / ≥ 2 ≥ 2 ≥10
, .
4
, (),
| (I) | , . . , . |
| , . . . . . , : ; ; , . , , ( ). . , . | |
| , 200 . . , . | |
| 60 . , , . ³ , (30-120 /.). , , , . | |
| - , , . , . . |
| , 60 200 , . , 30 /. , . , 20 . , . , , . | |
| ij . , , . . ( 20/). | |
| ij , . , , , . | |
| , . ϳ ﳿ, , . , : ; ; ; . |
5
, (),
'
³ :
, , ;
;
, , . ;
, ;
, , ;
;
, - , 璿 , ;
, .
:
, , (, , , , , );
;
䳺 ( !), ;
³ .
:
, ;
;
;
.
/, :
, ;
, ;
, ;
³ , .
ϳ :
, ﳿ / 1 50% , , ;
, , , ;
ϳ .
:
, ;
, ;
; , ;
˳ .
:
;
;
²;
.
:
;
ϳ ;
;
/ .
NB! .
, :
˳, ;
;
;
/ ;
ǒ .
6
, (),
7
, (),
, .
.
, (. 6. ' ).
, .
.
.
.
( ﳿ).
, , .
( ) , , , .
, , ; ; ; .
.
, .
, . , : , (, . .).
, , - , .
8
, (),
() - / . :
, , ( );
` ( );
.
9
, (),
| г | |||||||
| , | г , % | ||||||
| 31,5-42 | 1. -20.; 2. 40-45 3. - 4,3-4,5 , 4. - 25-33 / 5. 16-20 , 10 / 6. 5-8 | 4 - | |||||
| - | 21-31 | 50-74 | 1. -15 2. 35-40 . 3. - 2,7-3,5 , 90-120 4. 21-30 / | 3- | |||
| - | 10,5-21 | 35-49 | 1. -10-15 2. 30-35 3. 1,9-2,7 , 80-110 4. 12,5-21 / 6-8 . | 2- - | |||
| V | 2,5-10,5 | 35 | 1. -10-12 2. 10-12 3. 20-40 . 60-80 . | 1- |
;
㳺 ;
;
.
10
, (),
ﳿ, , .
䳿 :
- (, ) - () 15º 5 8 ;
- 20º ( (21-22 º) ( 22 º)) , 10-20 . ,
| , 1 | ||||
| 20-40 | 20 *2 3-5 | 17-18 | ||
| I | 20 *2 2-3 | 12-15 | ||
| 20 *2 1-2 | 10-12 |
- ;
- () 20 º 21º.
- ( ), , , - (), ( .. / .. // / .. , .., .. , .. , .. . - ., 1997. - .10. . 105-106) . 21-30º. 12-24 .
| ٳ 㳿, 2 | ||||
| 200 2 2 | 17-26 | |||
| I | 200 2 | 23-26 | ||
| 200-400 | 2400-4800 | 200 2 |
- -, . , , , 䒺 . , , , . 3-5 ˉ³, 80-90%- 5 . ʳ 100-700 ˉ³. 7-22º, 40-75%. 1-5 , 12 ( 20:00 8:00 ). 18-23 .
˳-
. ˳ - () . 20 40 :
1. (15-25% ) ;
2. ( 75% ) ;
3. (15% ) , , .
. ˳ , , ᒺ 1 (1).
. 㳺 (). . 5 15 . , , .
. - , - 䳿 , , . , , , ,
